Detalles de la búsqueda
1.
Discovery of novel pyridinones as MGAT2 inhibitors for the treatment of metabolic disorders.
Bioorg Med Chem Lett
; 91: 129362, 2023 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37295614
2.
Dihydropyrrolopyrazol-6-one MCHR1 antagonists for the treatment of obesity: Insights on in vivo efficacy from a novel FLIPR assay setup.
Bioorg Med Chem Lett
; 25(14): 2793-9, 2015 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26022839
3.
Non-basic azolotriazinone MCHR1 antagonists for the treatment of obesity: An empirical brain-exposures-driven candidate selection for in vivo efficacy studies.
Bioorg Med Chem Lett
; 25(20): 4412-8, 2015 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26386604
4.
Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.
Bioorg Med Chem Lett
; 23(1): 330-5, 2013 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23177783
5.
Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.
Bioorg Med Chem Lett
; 23(13): 3914-9, 2013 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23683593
6.
Discovery of 12 (BMS-986172) as a Highly Potent MGAT2 Inhibitor that Achieved Targeted Efficacious Exposures at a Low Human Dose for the Treatment of Metabolic Disorders.
J Med Chem
; 66(18): 13135-13147, 2023 09 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-37724542
7.
Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders.
J Med Chem
; 64(19): 14773-14792, 2021 10 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-34613725
8.
Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.
Bioorg Med Chem Lett
; 20(3): 1128-33, 2010 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20022752
9.
Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.
J Med Chem
; 50(6): 1365-79, 2007 Mar 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-17315987
10.
Utilization of an Active Site Mutant Receptor for the Identification of Potent and Selective Atypical 5-HT2C Receptor Agonists.
J Med Chem
; 60(14): 6166-6190, 2017 07 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-28635286
11.
An Enantiomer of an Oral Small-Molecule TSH Receptor Agonist Exhibits Improved Pharmacologic Properties.
Front Endocrinol (Lausanne)
; 7: 105, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27512388
12.
Identification of a nonbasic melanin hormone receptor 1 antagonist as an antiobesity clinical candidate.
J Med Chem
; 57(18): 7509-22, 2014 Sep 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-25165888
13.
Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.
J Med Chem
; 56(23): 9586-600, 2013 Dec 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-24182233
14.
Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy of the series.
Bioorg Med Chem Lett
; 17(14): 3978-82, 2007 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17513109
15.
In vivo pharmacological characterization of indiplon, a novel pyrazolopyrimidine sedative-hypnotic.
J Pharmacol Exp Ther
; 311(2): 547-59, 2004 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-15256538
Resultados
1 -
15
de 15
1
Próxima >
>>